Welcome to our dedicated page for Xilio Therapeutics SEC filings (Ticker: XLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xilio Therapeutics, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing masked immuno-oncology therapies. Its 8-K reports cover financial results, pipeline and business updates, investor presentations, material agreements, capital-structure matters, and clinical or regulatory disclosures tied to its masked I-O programs.
Proxy statements and related 8-K filings describe stockholder votes, director elections, board and committee changes, auditor ratification, equity incentive plans, and amendments affecting common stock. The filing record also includes disclosures related to reverse stock split matters, security-holder rights, director compensation, and governance arrangements for the company’s Delaware corporate structure.
Xilio Therapeutics, Inc. reported governance and compensation updates from its 2026 annual stockholder meeting. To rebalance its staggered board, Daniel Curran, M.D. resigned as a Class II director immediately after being re-elected and was reappointed as a Class III director with no changes to his compensation.
Stockholders elected four Class II directors—Akintunde Bello, Ph.D., Dr. Curran, Robert Ross, M.D., and Yuan Xu, Ph.D.—to terms expiring at the 2029 annual meeting. They also ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
In addition, stockholders approved an amendment to the 2021 Stock Incentive Plan so that shares underlying outstanding prefunded warrants are included with outstanding common stock when calculating the plan’s annual evergreen increase, potentially affecting future equity award capacity.
Xilio Therapeutics, Inc. filed Amendment No. 1 to its shelf registration (Form S-3/A) to update the registration following subsequent sales under a prior shelf and to refresh exhibits. The registration statement provides a base shelf permitting up to $250,000,000 of securities and a sales agreement prospectus for up to $14,500,000 of common stock to be sold under an at-the-market agreement with Leerink Partners LLC.
The amendment discloses that the company issued and sold $4,596,248 of securities under a prior S-3 (File No. 333-285703), updates the filing fee table, revises the public float calculation and prospectus exhibits (legal opinion and auditor consent), and supplies the base prospectus text describing possible securities, plan of distribution, and risk factors. The filing states a public float of $57,598,009 based on 6,575,139 shares outstanding as of May 26, 2026, and includes referenced prices of $8.35 (May 26, 2026 last sale) and $8.81 (price used for a prior calculation).
Xilio Therapeutics reported that OrbiMed Advisors LLC and affiliated OrbiMed Capital GP X LLC disclosed beneficial ownership positions in Common Stock. The filing shows OrbiMed Advisors beneficially owns 642,000 shares (9.99%) and OrbiMed GP beneficially owns 481,500 shares (7.49%) as disclosed with a reporting date of 03/31/2026. The filing states the positions arise upon conversion of warrants in the aggregate and that investment and voting power is exercised through a management committee.
Xilio Therapeutics, Inc. ownership disclosure: a group of Bain Capital Life Sciences entities filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 9.99% of Common Stock, equal to 664,021 shares as of March 31, 2026.
The filing states that BCLS II Equity holds a pre-funded warrant to purchase up to 1,116,245 shares but is contractually blocked from exercising if it would cause the Reporting Persons to exceed the 9.99% Beneficial Ownership Blocker. The ownership calculation uses 5,982,839 shares outstanding as reported in the Issuer's Definitive Proxy Statement dated April 28, 2026.
Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen filed an Amendment No. 2 on a Schedule 13G/A reporting 0% beneficial ownership of Xilio Therapeutics common stock as of the close of business on March 31, 2026.
The filing states the reporting persons have no sole or shared voting or dispositive power over Xilio common shares per the cover page rows incorporated by reference. The signature block shows the amendment was signed by an authorized person on May 15, 2026.
Xilio Therapeutics disclosure: Sirenia Capital Management and Alex Silverstein report beneficial ownership of 1,142,862 shares of Common Stock, equal to 9.9% of the class based on March 18, 2026 outstanding shares. The reported total includes 857,148 shares issuable upon exercise of the Reported Warrants, which are subject to a 9.99% Blocker; as a result, the Reporting Persons cannot exercise the warrants to exceed the blocker.
The percentage calculation uses an aggregate of 5,782,511 shares outstanding as of March 18, 2026, per the issuer's Form 10-K. The filing is made jointly by Sirenia and Mr. Silverstein under a Joint Filing Agreement.
Xilio Therapeutics, Inc. has filed a shelf registration to offer up to $250,000,000 of securities, which may include common stock, preferred stock, debt securities, units and warrants. The filing also includes a sales agreement prospectus permitting the issuance and sale of up to $17,220,000 of common stock under an at-the-market sales agreement with Leerink Partners LLC. The prospectus states the net proceeds will be used for general corporate purposes, including research and development and clinical trials, and that specific terms for each offering will be provided in prospectus supplements. The prospectus discloses 5,982,839 shares outstanding as of May 7, 2026 and a public float of $51,666,386 as of May 11, 2026, and reports a last reported sale price of common stock of $7.73 per share on May 11, 2026.
Xilio Therapeutics reported Q1 2026 results with collaboration and license revenue of $12.6 million and a net loss of $9.5 million. Revenue rose sharply from $2.9 million a year earlier, driven by AbbVie and Gilead agreements. Operating expenses increased to $26.8 million as the company advanced its masked immuno-oncology pipeline.
Cash and cash equivalents were $150.3 million as of March 31, 2026, plus $1.8 million of restricted cash. Xilio expects this cash, together with a $6.0 million AbbVie milestone achieved in Q2 2026, to fund operations into early 2028, excluding any additional milestones or warrant exercises.
Xilio Therapeutics reported first quarter 2026 results and pipeline progress. Collaboration and license revenue rose to $12.6 million from $2.9 million a year earlier, driven by AbbVie and Gilead agreements.
R&D expenses increased to $19.8 million, while G&A decreased to $6.9 million. Net loss narrowed to $9.5 million from $13.3 million. Cash and cash equivalents were $150.3 million as of March 31, 2026, helped by $37.3 million in net proceeds from a February 2026 follow-on offering.
The company achieved a $6.0 million development milestone under its AbbVie collaboration and now expects its cash, plus this milestone, to fund operations into early 2028. Xilio outlined plans for an IND filing and a Phase 1 trial for XTX501 in 2026, IND-enabling activities for multiple masked T cell engager programs, and an option data package for efarindodekin alfa in the first half of 2027.